Basic fibroblast growth factor is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. This protein functions as a modifier of endothelial cell migration and proliferation, as well as an angiogenic factor. It acts as a mitogen for a variety of mesoderm- and neuroectoderm-derived cells in vitro, thus is thought to be involved in organogenesis. Three alternatively spliced variants encoding different isoforms have been described. The heparin-binding growth factors are angiogenic agents in vivo and are potent mitogens for a variety of cell types in vitro. There are differences in the tissue distribution and concentration of these 2 growth factors.

Fibroblast Growth Factor-2 Human Recombinant (FGF-2) produced in E. coli is a single, non-glycosylated, polypeptide chain containing 155 amino acids and having a molecular mass of 17353 Dalton. The FGF-b is purified by proprietary chromatographic techniques. The protein was lyophilized from a concentrated (1mg/ml) solution in PBS, pH 7.4. Purity is greater than 96.0% as determined by RP-HPLC and SDS-PAGE. The ED50, calculated by the dose-dependant proliferation of BAF3 cells expressing FGF receptors (measured by 3H-thymidine uptake) is <0.5 ng/ml, corresponding to a specific activity of 2 x 10⁶ units/mg.

Protein quantitation was carried out by two independent methods: 1)UV spectroscopy at 280 nm using the absorbency value of 0.8511 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2) Analysis by RP-HPLC, using a calibrated solution of Fibroblast Growth Factor-b as a Reference Standard.

Amino Acid Sequence: MAAGSITTLP ALPEDGGSGA FPPGHFKDPK RLYCKNGGFF LRIHPDGRVD GVREKSDPHI KLQLQAEERG VVSIKGVCAN RYLAMKEDGR LLASKCVTDE CFFFERLESN NYNTYRSRKY TSWYVALKRT GQYKLGSKTG PGQKAILFLP MSAKS.

Advanced Targeting Systems(ATS)位于美国加州圣地亚哥， 成立于1994年。 公司发起人Douglas Lappi和Ronald Wiley博士在实验室开发出先进的分子神经外科学研究技术。ATS主要生产用于科研和药物研发的靶向试剂，公司在疼痛和药物转运的研究及临床治疗的两个产品已获专利保护。目前，产品包括靶向毒素 (可提供基底前脑胆碱能神经元、去甲肾上腺素能和肾上腺素能神经元、巨噬细胞和小胶质细胞的特异性损伤试剂等)、二抗生物素、神经元抗体、神经递质抗体、蛋白质和荧光结合物、免疫毒素对照等。